Gut bacterial tyrosine decarboxylases restrict levels of levodopa in the treatment of Parkinson’s disease
The gut microbiota can impact the bioavailability of therapeutic drugs. Here, the authors show that bacterial tyrosine decarboxylases (TDC) decrease the levels of levodopa, the primary treatment in Parkinson’s disease, by conversion to dopamine, and suggest TDC as a potential predictive biomarker fo...
Saved in:
Main Authors: | Sebastiaan P. van Kessel, Alexandra K. Frye, Ahmed O. El-Gendy, Maria Castejon, Ali Keshavarzian, Gertjan van Dijk, Sahar El Aidy |
---|---|
Format: | article |
Language: | EN |
Published: |
Nature Portfolio
2019
|
Subjects: | |
Online Access: | https://doaj.org/article/b417af8f89cb4dab815828a72e3ff5dd |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Protein intake and the use of levodopa in patients with Parkinson's disease
by: de Moraes Fracasso,Bianca, et al.
Published: (2013) -
Correlation between Serum Zinc Levels and Levodopa in Parkinson’s Disease
by: Hirofumi Matsuyama, et al.
Published: (2021) -
Levodopa-induced dyskinesias in Parkinson’s disease: emerging treatments
by: Bargiotas P, et al.
Published: (2013) -
Optimizing levodopa therapy for Parkinson’s disease with levodopa/carbidopa/entacapone: implications from a clinical and patient perspective
by: David J Brooks
Published: (2008) -
Exome-wide association study of levodopa-induced dyskinesia in Parkinson’s disease
by: Eva König, et al.
Published: (2021)